Researchers found that the FDA has given positive feedback regarding a new treatment called Privosegtor for acute multiple sclerosis (MS) relapses. This feedback supports Oculis Holding AG’s plans to submit an Investigational New Drug (IND) application for Privosegtor by late 2026. The treatment is designed to protect nerve cells and potentially improve recovery from acute MS relapses, which are episodes where symptoms worsen significantly.

This development is crucial for the approximately 850,000 people in the U.S. living with MS, a condition that can lead to lasting disabilities. Current treatments primarily focus on reducing the frequency of relapses but do not effectively address the long-term damage caused during these episodes. Privosegtor aims to fill this gap by preserving nerve function and potentially enhancing recovery after relapses, which could lead to better long-term outcomes for individuals with MS.

The evidence for Privosegtor’s effectiveness comes from a previous Phase 2 study called ACUITY, which demonstrated its neuroprotective effects in optic neuritis, a common type of MS relapse. While the results are promising, it’s important to note that further clinical trials are needed to confirm its benefits specifically for acute MS relapses. The FDA’s support indicates a clear regulatory pathway, but the treatment is still in the investigational stage and has not yet been approved for general use.

As Oculis continues its development, those interested in MS treatments should stay informed about Privosegtor’s progress and consider discussing emerging options with their healthcare providers.

Source